首页> 外文期刊>Journal of Translational Medicine >Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1
【24h】

Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1

机译:基于链霉亲和素-生物素的定向双纳米抗体夹心ELISA用于临床快速灵敏检测H5N1流感

获取原文
       

摘要

Background Influenza H5N1 is one subtype of the influenza A virus which can infect human bodies and lead to death. Timely diagnosis before its breakout is vital to the human health. The current clinical biochemical diagnosis for influenza virus are still flawed, and the diagnostic kits of H5N1 are mainly based on traditional monoclonal antibodies that hardly meet the requirements for clinical applications. Nanobody is a promising tool for diagnostics and treatment due to its smallest size, high specificity and stability. In this study, a novel Nanobody-based bioassay was developed for rapid, low-cost and sensitive detection of the influenza H5N1 virus. Methods Nanobodies specific to H5N1 virus were selected from a VHH library by phage display technology. In this system, the biotinylated Nanobody was directionally captured by streptavidin coated on ELISA plate, which can specifically capture the H5N1 virus. Another Nanobody conjugated with HRP was used as a detector. A novel directional enzyme-linked immunosorbent assay for H5N1 using specific Nanobodies was established and compared to the conventional undirected ELISA assay. Results We have successfully constructed a high quality phage display Nanobody library and isolated two Nanobodies against H5N1 with high affinity and specificity. These two Nanobodies were further used to prepare the biosensor detection system. This streptavidin-biotin-based directional double Nanobodies sandwich ELISA for H5N1 detection showed superiority over the commonly undirectional ELISA protocol. The linear range of detection for standards in this immunoassay was approximately 50–1000?ng/mL and the detection limit was 14.1?ng/mL. The average recoveries of H5N1 virus from human serum samples were in the range from 94.58% to 114.51%, with a coefficient of variation less than 6.5%. Conclusion Collectively, these results demonstrated that the proposed detection system is an alternative diagnostic tool that enables a rapid, inexpensive, sensitive and specific detection of the influenza virus.
机译:背景H5N1流感是可感染人体并导致死亡的A型流感病毒的一种亚型。爆发前及时诊断对人体健康至关重要。目前对流感病毒的临床生化诊断仍存在缺陷,H5N1诊断试剂盒主要基于难以满足临床应用要求的传统单克隆抗体。纳米抗体因其最小的尺寸,高的特异性和稳定性而成为诊断和治疗的有前途的工具。在这项研究中,开发了一种新颖的基于纳米抗体的生物测定法,用于快速,低成本和灵敏地检测H5N1流感病毒。方法通过噬菌体展示技术从VHH文库中选择H5N1病毒特异的纳米抗体。在该系统中,生物素化的纳米抗体是通过包被在ELISA板上的抗生蛋白链菌素定向捕获的,可以特异性捕获H5N1病毒。与HRP共轭的另一种纳米抗体被用作检测器。建立了一种使用特异性纳米抗体的H5N1新型定向酶联免疫吸附试验,并将其与常规无方向ELISA试验进行了比较。结果我们已经成功构建了高质量的噬菌体展示纳米抗体文库,并以高亲和力和特异性分离了两个针对H5N1的纳米抗体。这两个纳米抗体进一步用于制备生物传感器检测系统。这种基于链霉亲和素-生物素的定向双纳米抗体夹心ELISA用于H5N1检测显示出优于通常无方向ELISA方案的优越性。在该免疫测定中,标准品的线性检测范围约为50–1000?ng / mL,检测极限为14.1?ng / mL。 H5N1病毒从人血清样品中的平均回收率在94.58%至114.51%的范围内,变异系数小于6.5%。结论总的来说,这些结果表明,所提出的检测系统是一种备选的诊断工具,能够快速,廉价,灵敏和特异地检测流感病毒。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号